NCT03406871: Regorafenib and Nivolumab Simultaneous Combination Therapy

NCT03406871
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are not eligible for the expansion phase
Exclusions:  Symptomatic brain metastasis
https://ClinicalTrials.gov/show/NCT03406871

Comments are closed.

Up ↑